REVIEW OF: Pagan FL et al, CNS Drugs 2024;38(5):333–347 STUDY TYPE: Expert consensus review
Parkinson’s disease psychosis (PDP) affects roughly 40% of patients and puts us in a bind: Antipsychotics help, but they risk worsening motor symptoms and increasing mortality. This industry-funded expert panel (all four authors have financial ties to Acadia Pharmaceuticals, pimavanserin’s manufacturer) reviewed current evidence and proposed a treatment algorithm.
Before you reach for any antipsychotic, the authors recommend ruling out reversible causes: delirium, infection, metabolic disturbances, and PD medications themselves. Simplify the regimen first. For mild, non-distressing symptoms, hold off on medication entirely and try psychoeducation, better lighting, and sleep optimization.
When psychosis becomes bothersome or impairing, the panel recommends pimavanserin 34 mg once daily as first line. In its pivotal trial, pimavanserin reduced symptoms significantly more than placebo (5.79 vs 2.73 points on the Scale for the Assessment of Positive Symptoms—Parkinson Disease; p = 0.001) without worsening motor function. Long-term open-label data suggest benefit lasting four or more years.
Clozapine has the strongest randomized trial evidence for efficacy in PDP, but it requires blood count monitoring. Quetiapine is widely used for convenience but has weak efficacy data; the panel sees it as a fallback option only.
CARLAT TAKE The case for pimavanserin as first line is reasonable, but take this algorithm with a grain of salt—it rests on indirect comparisons and expert opinion, not head-to-head trial data, and the research was industry-funded. That said, the practical advice is sound: Before starting pimavanserin, check for reversible contributors and simplify the PD regimen. Once you prescribe, warn patients that response takes four to six weeks. Cost (as much as $3,500/month) is the main real-world obstacle, and almost all insurers will require prior authorization, though some manufacturers offer assistance programs.
